CompletedPhase 1

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoint

•Area under the Curve (AUC) glucagon

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01509742

Org study IDNN2211-1224

Timeline

Milestones

Study first posted2012-01-13estimated

Last update posted2024-02-01actual

Study start2001-04 (month precision)

Primary completion2001-11actual (month precision)

Study completion2001-11actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age30 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

age: minimum 30, maximum 75 years

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint/low confidence

Insulin secretion

descriptive, improvement

Secondary/protocol endpoint/low confidence

Glucose

descriptive, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

Area under the Curve (AUC) glucagon

descriptive

Secondary/protocol endpoint/low confidence

Cortisol

descriptive

Secondary/protocol endpoint/low confidence

Growth hormone

descriptive

Secondary/protocol endpoint/low confidence

Adrenaline

descriptive

Secondary/protocol endpoint/low confidence

Noradrenaline

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.